Friday, July 10, 2026

Drug profile · INN

enalaprilat

enalaprilat (ENALAPRILAT) is a angiotensin-converting enzyme inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — enalaprilat
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

enalaprilat (ENALAPRILAT) is a angiotensin-converting enzyme inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN enalaprilat
Brand ENALAPRILAT
Mechanism Angiotensin-converting enzyme inhibitor
Target Angiotensin-converting enzyme
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Angiotensin-converting enzyme inhibitor

Primary target: Angiotensin-converting enzyme

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. benazepril hydrochloride Angiotensin-converting enzyme inhibitor
  2. captopril Angiotensin-converting enzyme inhibitor
  3. enalapril maleate Cardiovascular system (C09)
  4. fosinopril sodium Angiotensin-converting enzyme inhibitor
  5. lisinopril Angiotensin-converting enzyme inhibitor
  6. moexipril hydrochloride Angiotensin-converting enzyme inhibitor

Frequently asked questions

What is enalaprilat?

enalaprilat (ENALAPRILAT) is a angiotensin-converting enzyme inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for enalaprilat?

ENALAPRILAT is a marketed brand name for enalaprilat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of enalaprilat?

enalaprilat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.